Survival benefit of switching to anastrozole after 2 years' treatment with tamoxifen versus continued tamoxifen therapy: The ARNO 95 study.

@article{Kaufmann2006SurvivalBO,
  title={Survival benefit of switching to anastrozole after 2 years' treatment with tamoxifen versus continued tamoxifen therapy: The ARNO 95 study.},
  author={Manfred Kaufmann and Walter Jonat and Joern Hilfrich and Holger Eidtmann and G{\"u}nther Gademann and Ivan Zuna and Gunter von Minckwitz},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 18_suppl},
  pages={547}
}
547 Background: Initial adjuvant treatment with anastrozole has significant efficacy and tolerability advantages over tamoxifen in postmenopausal women with hormone-sensitive early breast cancer (EBC) (ATAC Trialists' Group. Lancet 2005; 365: 60-62). The ARNO 95 study evaluated prospectively switching to anastrozole from tamoxifen after 2 years, compared… CONTINUE READING